Almirall Surpasses €1 Billion in Sales, Driven by Biologics Growth
Event summary
- Almirall reported €1.11 billion in total revenue for 2025, up 12.5% year-over-year, surpassing the €1 billion mark in net sales.
- EBITDA increased by 21.0% to €232.9 million, with a gross margin of 64.4%.
- Net income rose significantly to €46.2 million from €10.1 million in 2024.
- Biologics Ilumetri® and Ebglyss® were key growth drivers, with sales of €234.4 million and €110.8 million respectively.
- R&D investment reached €138.1 million, representing 12.5% of net sales.
The big picture
Almirall's strong financial performance in 2025 underscores its leadership in medical dermatology, driven by the success of its biologics portfolio. The company's sustained growth trajectory and strategic investments in R&D position it well to capitalize on the increasing prevalence of skin conditions and the demand for advanced treatment options. The biopharmaceutical sector's focus on specialized therapies and the expanding market for dermatological solutions further reinforce Almirall's strategic relevance.
What we're watching
- Product Pipeline
- The progress of key developmental assets through clinical testing, including an anti-IL-1RAP monoclonal antibody targeting hidradenitis suppurativa, will be critical to watch.
- Market Expansion
- The continued expansion of Ebglyss® across European markets and its growth trajectory towards expected peak sales above €450 million will be a key indicator of success.
- Regulatory Approvals
- The approval of Efinaconazole in Germany and Sarecycline in China for new indications will impact Almirall's market reach and revenue streams.
Related topics